{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:39Z","timestamp":1791417639868,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R44GM122196-02A1"],"award-info":[{"award-number":["R44GM122196-02A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R44ES031038-02"],"award-info":[{"award-number":["R44ES031038-02"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dmd.2025.100160","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:17:01Z","timestamp":1757467021000},"page":"100160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4015-6410","authenticated-orcid":false,"given":"Patricia A.","family":"Vignaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2025.100160_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/cts.13347","article-title":"Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population","volume":"15","author":"Br\u00e5ten","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.dmd.2025.100160_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/dmd.119.090407","article-title":"Stereoselective bupropion hydroxylation by cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase genetic variants","volume":"48","author":"Wang","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100160_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/dmd.119.086348","article-title":"Efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100160_bib5","doi-asserted-by":"crossref","first-page":"e00947","DOI":"10.1128\/AAC.00947-19","article-title":"Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes","volume":"64","author":"Abdullahi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2025.100160_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cpt.3338","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2B6 genotype and methadone therapy","volume":"116","author":"Robinson","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100160_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s43440-023-00455-7","article-title":"Effect of common OPRM1, COMT, SLC6A4, ABCB1, and CYP2B6 polymorphisms on perioperative analgesic and propofol demands on patients subjected to thyroidectomy surgery","volume":"75","author":"Soultati","year":"2023","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.dmd.2025.100160_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1081\/DMR-100101942","article-title":"The role of CYP2B6 in human xenobiotic metabolism","volume":"31","author":"Ekins","year":"1999","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.dmd.2025.100160_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/138920008784746346","article-title":"Molecular characterization of CYP2B6 substrates","volume":"9","author":"Ekins","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.dmd.2025.100160_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib12","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1038\/s41598-022-07022-9","article-title":"CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function","volume":"12","author":"Mang\u00f3","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.dmd.2025.100160_bib13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acs.molpharmaceut.8b01214","article-title":"Halogen substitution influences ketamine metabolism by cytochrome P450 2B6: in vitro and computational approaches","volume":"16","author":"Wang","year":"2019","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3565(24)37919-4","article-title":"Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6","volume":"288","author":"Ekins","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"10.1016\/j.dmd.2025.100160_bib15","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.3390\/molecules26154678","article-title":"CYPstrate: a set of machine learning models for the accurate classification of cytochrome P450 enzyme substrates and non-substrates","volume":"26","author":"Holmer","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.dmd.2025.100160_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1021\/acs.chemrestox.4c00168","article-title":"Machine learning-based in silico prediction of the inhibitory activity of chemical substances against rat and human cytochrome P450s","volume":"37","author":"Ambe","year":"2024","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13321-025-01015-2","article-title":"Improving the accuracy of prediction models for small datasets of cytochrome P450 inhibition with deep learning","volume":"17","author":"Permadi","year":"2025","journal-title":"J Cheminform"},{"issue":"7","key":"10.1016\/j.dmd.2025.100160_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/omi.2023.0075","article-title":"A robust machine learning framework built upon molecular representations predicts CYP450 inhibition: toward precision in drug repurposing","volume":"27","author":"Ouzounis","year":"2023","journal-title":"OMICS"},{"issue":"8","key":"10.1016\/j.dmd.2025.100160_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acs.chemrestox.3c00065","article-title":"Machine learning models to predict cytochrome P450 2B6 inhibitors and substrates","volume":"36","author":"Li","year":"2023","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","volume":"110","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"D1","key":"10.1016\/j.dmd.2025.100160_bib21","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41524-025-01573-x","article-title":"A general approach for determining applicability domain of machine learning models","volume":"11","author":"Schultz","year":"2025","journal-title":"npj Comput Mater"},{"issue":"5","key":"10.1016\/j.dmd.2025.100160_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acs.chemrestox.5c00033","article-title":"Machine learning for toxicity prediction using chemical structures: pillars for success in the real world","volume":"38","author":"Seal","year":"2025","journal-title":"Chem Res Toxicol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100160_bib24","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.molpharmaceut.8b00083","article-title":"Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery","volume":"15","author":"Lane","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2025.100160_bib25","first-page":"2579","article-title":"Visualizing data using t-SNE","volume":"9","author":"van der Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13321-024-00883-4","article-title":"Hamiltonian diversity: effectively measuring molecular diversity by shortest Hamiltonian circuits","volume":"16","author":"Hu","year":"2024","journal-title":"J Cheminform"},{"issue":"6","key":"10.1016\/j.dmd.2025.100160_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/ci010132r","article-title":"Reoptimization of MDL keys for use in drug discovery","volume":"42","author":"Durant","year":"2002","journal-title":"J Chem Inf Comput Sci"},{"issue":"8-9","key":"10.1016\/j.dmd.2025.100160_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/minf.201000063","article-title":"The one-class classification approach to data description and to models applicability domain","volume":"29","author":"Baskin","year":"2010","journal-title":"Mol Inform"},{"issue":"3","key":"10.1016\/j.dmd.2025.100160_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100160_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/mol.111.074427","article-title":"Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains","volume":"80","author":"Shah","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100160_bib31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.114.060459","article-title":"Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds","volume":"42","author":"Bolles","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12931-022-02164-w","article-title":"Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate\/vilanterol: a randomized controlled trial","volume":"23","author":"Daley-Yates","year":"2022","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.dmd.2025.100160_bib33","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/bcp.12019","article-title":"The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects","volume":"75","author":"Kempsford","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100160_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12884-023-05970-2","article-title":"Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.dmd.2025.100160_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114368","article-title":"Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library","volume":"184","author":"Lynch","year":"2021","journal-title":"Biochem Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:16:15Z","timestamp":1761714975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562509169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S009095562509169X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100160","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100160"}}